Table 1 Baseline demographic and clinical characteristics
BTC cohort (n = 27) | PDAC cohort (n = 24) | |
|---|---|---|
Age (years), median (range) | 62 (45–77) | 61 (35–77) |
Gender, n (%) | ||
Male | 10 (37.0) | 17 (70.8) |
Female | 17 (63.0) | 7 (29.2) |
ECOG PS, n (%) | ||
0 | 0 | 0 |
1 | 27 (100.0) | 24 (100.0) |
Primary tumor histology, n (%) | ||
Pancreatic ductal adenocarcinoma | – | 24 (100.0) |
Intrahepatic cholangiocarcinoma | 14 (51.9) | – |
Extrahepatic cholangiocarcinoma | 5 (18.5) | – |
Gallbladder adenocarcinoma | 8 (29.6) | – |
Metastatic sites | ||
Liver | 22 (81.5) | 18 (75.0) |
Lung | 10 (37.0) | 15 (62.5) |
Peritoneum | 8 (29.6) | 13 (54.2) |
Bone | 2 (7.4) | 1 (4.2) |
Distant lymph node | 8 (29.6) | 1 (4.2) |
Other | 5 (18.5) | 3 (12.5) |
Number of metastatic sites, n (%) | ||
1 | 9 (33.3) | 8 (33.3) |
2 | 10 (37.0) | 6 (25.0) |
≥3 | 8 (29.6) | 10 (41.7) |
Sum of diameter (mm), median (range) | 58 (10–188) | 58 (17–121) |
Lines of previous systemic treatment, n (%) | ||
One | 17 (63.0) | 11 (45.8) |
Two | 7 (25.9) | 6 (25.0) |
Three or more | 2 (7.4) | 7 (29.2) |
Median (range) | 1(0*-3) | 2(1–4) |
Prior cancer treatment, n (%) | ||
Primary tumor resection | 18 (66.7) | 16 (66.7) |
Radiation therapy | 4 (14.8) | 0 |
Ablation therapy | 13 (48.1) | 7 (29.2) |
Intra-arterial therapy# | 12 (44.4) | 10 (41.7) |
Chemotherapy | 26 (96.3) | 24 (100.0) |
